SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-022893
Filing Date
2020-05-07
Accepted
2020-05-07 16:21:57
Documents
59
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-10q_20200331.htm 10-Q 1759310
2 EX-31.1 trvi-ex311_6.htm EX-31.1 14064
3 EX-31.2 trvi-ex312_9.htm EX-31.2 13915
4 EX-32.1 trvi-ex321_7.htm EX-32.1 8640
5 EX-32.2 trvi-ex322_8.htm EX-32.2 8747
  Complete submission text file 0001564590-20-022893.txt   4825366

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT trvi-20200331.xml EX-101.INS 793395
7 XBRL TAXONOMY EXTENSION SCHEMA trvi-20200331.xsd EX-101.SCH 42694
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE trvi-20200331_cal.xml EX-101.CAL 34783
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE trvi-20200331_def.xml EX-101.DEF 92369
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20200331_lab.xml EX-101.LAB 302581
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20200331_pre.xml EX-101.PRE 226199
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 20856791
SIC: 2834 Pharmaceutical Preparations